HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warnings Mark Tip Of Iceberg For Stimulant-Spiked Supplements – Study

This article was originally published in The Tan Sheet

Executive Summary

Researchers' "particular concern" about the stimulant oxilofrine in sports nutrition supplements is that more than 1m youth athletes use the products. Based on labeling, adolescents could consume three times the highest pediatric dose allowed where oxilofrine is approved as a drug.

Advertisement

Related Content

DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study
Second Warning, Second Unsafe Ingredient For Total Body Nutrition
Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting
Researchers Suggest Supplement Sales Grow As Consumers Ignore Studies
Sharfstein Suggests Requiring Supplements Registration, Testing Standards

Topics

Advertisement
UsernamePublicRestriction

Register

RS108863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel